Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07032545 · ClinicalTrials.gov registry record · NA

Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors

A NA study of Obesity and Overweight and Breast Cancer Survivorship, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT07032545: Recruiting NA study of Obesity and Overweight and Breast Cancer Survivorship, sponsored by University of Maryland, Baltimore.

NCT07032545 is a NA study of Obesity and Overweight and Breast Cancer Survivorship that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 24 participants, below the 465-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07032545, a NA study of Obesity and Overweight and Breast Cancer Survivorship, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Obesity can pose significant challenges to maintaining long-term health in cancer survivors by increasing their risk of cancer coming back. Eating a healthy diet is an important way to help manage weight and improve overall health. Broccoli microgreens (BMG) are young broccoli plants packed with nutrients, and research suggests they may help prevent cancer. Previous studies in mice showed that BMG can improve gut health and metabolism, leading to better health outcomes in obese animals. This study will test whether BMG can be a useful addition to the diet of obese breast cancer (BC) survivors who have a higher risk of their cancer returning. 24 obese BC survivors will be invited to eat one serving (one cup, \~57 gram) of fresh BMG every day for two weeks. This will help understand if people can stick to this diet, how their bodies respond, and whether it affects metabolism and inflammation-two key factors linked to cancer risk. Biological markers such as body fat, glucose and lipids as well as gut bacterial changes will be analyzed to see how BMG affects individual health. This study may help create new diet strategies to improve health, reduce cancer risk, and support long-term recovery in cancer patients who are overweight or obese. In the future, this research could help doctors personalize nutrition plans to better support cancer survivors.

Primary Outcome

Feasibility will be assessed by calculating the percentage of participants who enrolled and completed the study by providing evaluable data at baseline, during the BMG intervention and after 2-weeks treatment.

Interventions

  • OTHER Broccoli microgreen (BMG)

Study Locations (1)

Maryland

  • Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center - Baltimore

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-12-03
Est. Completion 2028-12-31
Phase NA
University of Maryland, Baltimore

560 total trials

What NCT07032545 shows while recruiting

NCT07032545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 465-participant average among 27 other Obesity and Overweight trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Obesity and Overweight appearing as the primary indexed condition, and to 1 intervention - of which Broccoli microgreen (BMG) is the first listed.

NCT07032545 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT07032545 about?

NCT07032545 is a clinical study titled "Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors". Obesity can pose significant challenges to maintaining long-term health in cancer survivors by increasing their risk of cancer coming back. Eating a healthy diet is an important way to help manage weight and improve overall health. Broccoli microgreens (BMG) are young broccoli plants packed with nut...

What is the current status of trial NCT07032545?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-12-03. Estimated completion is 2028-12-31.

What conditions does trial NCT07032545 study?

This clinical trial studies the following conditions: Obesity and Overweight, Breast Cancer Survivorship.

What interventions are being tested in trial NCT07032545?

The interventions under investigation include: Broccoli microgreen (BMG) (OTHER).

Who is sponsoring clinical trial NCT07032545?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07032545 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity and Overweight

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07032545's enrollment target sits among peer trials

24 24th of 27 higher than 4 of 27 other Obesity and Overweight trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity and Overweight trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07032545, the US trial registry maintained by the National Library of Medicine. NCT07032545 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.